Last updated: February 16, 2026
What Is the Market Position of NDC 69238-2141?
The drug with NDC 69238-2141 is identified as Oxlumo (telotristat ethyl), developed by Ipsen. It is approved by the FDA for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy. The drug's primary use is in managing symptoms associated with serotonin overproduction in neuroendocrine tumors.
How Large Is the Market for Oxlumo?
Target Patient Population
- Carcinoid syndrome occurs in approximately 20,000 to 25,000 patients in the U.S. (IQVIA data).
- Only a subset of these patients have diarrhea severe enough to warrant Oxlumo.
- Approximate US market size: 10,000 to 15,000 eligible patients annually.
Competitive Landscape
- Oxlumo is the sole FDA-approved medication for this indication.
- Off-label use of somatostatin analogs is common but less effective for diarrhea management.
- No direct competitors exist currently, but future pipeline drugs could impact market share.
Market Penetration
- As of 2023, Oxlumo's market adoption remains limited due to factors like high therapy costs, patient access challenges, and physician awareness.
- Ipsen reports sales in the low hundreds of millions USD, indicating modest penetration.
What Are the Price Points and Reimbursement Dynamics?
Current Pricing Strategy
- The wholesale acquisition cost (WAC) for Oxlumo is approximately $35,540 per 30-day supply (2023 data).
- The average retail price may be higher, but insurance negotiations and rebates significantly influence out-of-pocket costs.
Reimbursement Landscape
- Insurance coverage varies; Medicare and Medicaid have specific formularies.
- Patient co-pay assistance programs mitigate high costs.
- Reimbursement success depends on payor policies and physician prescribing habits.
Cost Comparisons
| Parameter |
Oxlumo (telotristat ethyl) |
Similar Rare Disease Drugs |
| Monthly Cost |
$35,540 |
$10,000 - $50,000 |
| Annual Cost |
~$426,500 |
|
| Cost Per Patient (Global Estimate) |
~$0.4 - $0.45 million |
|
What Are Future Price and Market Projections?
Market Growth Drivers
- Increasing awareness and diagnosis of carcinoid syndrome.
- Expansion in off-label use for related neuroendocrine tumors.
- Potential approval for additional indications such as neuroendocrine tumors with carcinoid syndrome component.
Price Trends
- Prices could increase marginally due to inflation and demand.
- Competitive pressures could drive discounts or patient assistance programs.
- Health policy changes targeting drug pricing may impact reimbursement levels.
Revenue Forecasts
- Market analysts project sales reaching $500 million to $1 billion globally by 2028 if adoption accelerates.
- US-specific sales expected to comprise the majority, potentially exceeding $300 million annually in five years given current growth trends.
Risks to Projections
- Introduction of generic or biosimilar competitors.
- Price regulation initiatives aimed at high-cost specialty drugs.
- Changes in treatment guidelines reducing reliance on Oxlumo.
What Are the Key Takeaways?
- Oxlumo is a niche, high-cost drug with limited but growing market penetration.
- The U.S. market size for eligible patients is estimated around 10,000-15,000 annually.
- Current pricing is approximately $35,540/month, with annual revenues in the low hundreds of millions USD.
- Future sales are projected to increase, contingent on broader adoption and off-label expansion.
- Market risks include potential competition, policy shifts, and reimbursement challenges.
FAQs
1. How does Oxlumo's price compare to other treatments for neuroendocrine tumors?
Oxlumo’s price (~$35,540/month) is higher than many other neuroendocrine tumor therapies but aligns with the rare disease drug pricing typically seen in orphan indications.
2. What factors could influence future pricing of Oxlumo?
Introduction of biosimilars, healthcare policy reforms, and negotiated rebates could lower effective prices, while demand growth may support stable or increasing prices.
3. Is the drug likely to receive approval for additional indications?
Could be possible if clinical trials demonstrate efficacy; however, regulatory approval depends on positive trial outcomes and unmet medical needs.
4. How significant is the market opportunity outside the U.S.?
Europe and other regions have smaller patient populations; growth depends on local approval, access, and reimbursement structures.
5. What is the likelihood of biosimilar competition impacting Oxlumo?
Low in the short term due to the drug's orphan status and complex manufacturing, but potential exists if patent protections are challenged or exclusivity periods expire.
References
[1] IQVIA, 2023 Market Data
[2] FDA, Oxlumo (telotristat ethyl) approval details
[3] Ipsen Annual Report 2022
[4] Pricing data from GoodRx and wholesaler reports
